NYR logo

Nyrada CHIA:NYR Stock Report

Last Price

AU$0.097

Market Cap

AU$19.9m

7D

-7.6%

1Y

n/a

Updated

22 Dec, 2024

Data

Company Financials

NYR Stock Overview

A pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. More details

NYR fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Nyrada Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Nyrada
Historical stock prices
Current Share PriceAU$0.097
52 Week HighAU$0.17
52 Week LowAU$0.019
Beta1.1
1 Month Change-3.00%
3 Month Change73.21%
1 Year Changen/a
3 Year Change-52.68%
5 Year Changen/a
Change since IPO-59.58%

Recent News & Updates

Recent updates

Shareholder Returns

NYRAU PharmaceuticalsAU Market
7D-7.6%-4.9%-2.7%
1Yn/a-9.3%6.5%

Return vs Industry: Insufficient data to determine how NYR performed against the Australian Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how NYR performed against the Australian Market.

Price Volatility

Is NYR's price volatile compared to industry and market?
NYR volatility
NYR Average Weekly Movement26.6%
Pharmaceuticals Industry Average Movement10.3%
Market Average Movement8.0%
10% most volatile stocks in AU Market16.8%
10% least volatile stocks in AU Market3.1%

Stable Share Price: NYR's share price has been volatile over the past 3 months compared to the Australian market.

Volatility Over Time: NYR's weekly volatility has decreased from 71% to 27% over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
2017n/aJames Bonnarwww.nyrada.com

Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. Its develops oral Proprotein Convertase Subtilisin/Kexin Type 9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs; and neuroprotectant drug to reduce long-term disability in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.

Nyrada Inc. Fundamentals Summary

How do Nyrada's earnings and revenue compare to its market cap?
NYR fundamental statistics
Market capAU$19.91m
Earnings (TTM)-AU$1.39m
Revenue (TTM)AU$3.24m

6.1x

P/S Ratio

-14.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NYR income statement (TTM)
RevenueAU$3.24m
Cost of RevenueAU$2.03m
Gross ProfitAU$1.21m
Other ExpensesAU$2.60m
Earnings-AU$1.39m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.0066
Gross Margin37.37%
Net Profit Margin-42.92%
Debt/Equity Ratio0%

How did NYR perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 10:02
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Nyrada Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution